Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

被引：8

作者：

Fiedler, Walter ^{[1
]}

Heuser, Michael ^{[2
]}

Chromik, Joerg ^{[3
]}

Thol, Felicitas ^{[2
]}

Bokemeyer, Carsten ^{[4
]}

Theile, Susann ^{[5
]}

Lebkuechner, Isabell ^{[5
]}

Kranich, Anne L. ^{[6
]}

机构：

[1] Univ Hosp Eppendorf, Dept Hematol & Oncol, Hamburg, Germany

[2] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany

[3] Univ Hosp Frankfurt, Frankfurt, Germany

[4] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Med Clin & Polyclin 2, Hamburg, Germany

[5] GSOmbH, Hamburg, Germany

[6] GSO Global B V, Amsterdam, Netherlands

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.341.341

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

341

引用

页数：6

共 50 条

[41] High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia:: a pharmacokinetic and clinical study
Tedeschi, Alessandra
Montillo, Marco
Strocchi, Elena
Cafro, Anna Maria
Tresoldi, Elisabetta
Intropido, Liliana
Nichelatti, Michele
Marbello, Laura
Barate, Claudia
Camaggi, Carlo Maurizio
Morra, Enrica
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) : 771 - 779
[42] Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
Sadowski, Abbey R.
Gardner, Heather L.
Borgatti, Antonella
Wilson, Heather
Vail, David M.
Lachowicz, Joshua
Manley, Christina
Turner, Avenelle
Klein, Mary K.
Waite, Angharad
Sahora, Alexandra
London, Cheryl A.
BMC VETERINARY RESEARCH, 2018, 14
[43] High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study
Alessandra Tedeschi
Marco Montillo
Elena Strocchi
Anna Maria Cafro
Elisabetta Tresoldi
Liliana Intropido
Michele Nichelatti
Laura Marbello
Claudia Baratè
Carlo Maurizio Camaggi
Enrica Morra
Cancer Chemotherapy and Pharmacology, 2007, 59 : 771 - 779
[44] Safety and antitumor activity of selinexor (KPT-330), a first-in -class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.
Mau-Soerensen, Morten
Razak, Albiruni R. A.
Mahipal, Amit
Mahaseth, Hemchandra
Gerecitano, John F.
Shacham, Sharon
Yau, Cindy Y. F.
Lassen, Ulrik
Shields, Anthony Frank
McCauley, Dilara
Cooksey, Jennifer
Tan, David Shao Peng
Rashal, Tami
Shacham, Eran
Landesman, Yosef
Pond, Gregory
Oza, Amit M.
Kauffman, Michael
Siu, Lillian
Mirza, Mansoor Raza
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[45] Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay
Patrick Daniele
Janis Breeze
Lingling Li
Jatin Shah
Sharon Shacham
Michael Kauffman
Monika Engelhardt
Ajaj Chari
Ajay Nooka
Dan Vogl
Maria Gavriatopoulou
Meletios-Athanasios Dimopoulos
Paul Richardson
Noa Biran
David Siegel
Philip Vlummens
Chantal Doyen
Thierry Facon
Mohamad Mohty
Nathalie Meuleman
Moshe Levy
Luciano Costa
James E. Hoffman
Michel Delforge
David Kaminetzky
Katja Weisel
Marc Raab
David Dingli
Sascha Tuchman
Frenzel Laurent
Ravi Vij
Gary Schiller
Philippe Moreau
Joshua Richter
Martin Schreder
Klaus Podar
Terri Parker
Robert Frank Cornell
Karlin Lionel
Sylvain Choquet
Jagannath Sundar
BMC Cancer, 21
[46] The effects of KPT-330, a selective inhibitor of nuclear export, on nuclear topoisomerase II alpha levels and etoposide activity in human myeloid leukemia HL-60 cells
Godley, Erica
Kanagasabai, Ragu
Karmahapatra, Soumendrakrishna
Yalowich, Jack C.
CANCER RESEARCH, 2016, 76
[47] QUALITY OF LIFE ANALYSES IN PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM THE SELINEXOR (KPT-330) TREATMENT OF REFRACTORY MYELOMA (STORM) PHASE 2B STUDY
Breeze, J.
Mehta, J.
Tremblay, G.
Shacham, S.
Shah, J.
Li, L.
Kauffman, M.
Jagannath, S.
VALUE IN HEALTH, 2020, 23 : S77 - S77
[48] Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Tremblay, Gabriel
Daniele, Patrick
Breeze, Janis
Li, Lingling
Shah, Jatin
Shacham, Sharon
Kauffman, Michael
Engelhardt, Monika
Chari, Ajaj
Nooka, Ajay
Vogl, Dan
Gavriatopoulou, Maria
Dimopoulos, Meletios-Athanasios
Richardson, Paul
Biran, Noa
Siegel, David
Vlummens, Philip
Doyen, Chantal
Facon, Thierry
Mohty, Mohamad
Meuleman, Nathalie
Levy, Moshe
Costa, Luciano
Hoffman, James E.
Delforge, Michel
Kaminetzky, David
Weisel, Katja
Raab, Marc
Dingli, David
Tuchman, Sascha
Laurent, Frenzel
Vij, Ravi
Schiller, Gary
Moreau, Philippe
Richter, Joshua
Schreder, Martin
Podar, Klaus
Parker, Terri
Cornell, Robert Frank
Lionel, Karlin
Choquet, Sylvain
Sundar, Jagannath
BMC CANCER, 2021, 21 (01)
[49] Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study.
Jagannath, Sundar
Mehta, Jyotsna
Breeze, Janis
Tremblay, Gabriel
Li, Lingling
Biran, Noa
Shacham, Sharon
Kauffman, Michael G.
Shah, Jatin J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers.
Vergote, Ignace
Lund, Bente
Havsteen, Hanne
Ujmajuridze, Zaza
Leunen, Karin
Haslund, Charlotte Aaquist
Juhler-Noettrup, Trine
Roed, Henrik
Rashal, Tami
Kranich, Anne L.
Landesman, Yosef
Saint-Martin, Jean-Richard
Carlson, Robert
Shacham, Sharon
Kauffman, Michael
Mirza, Mansoor Raza
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →